Why is Titan Biotech falling/rising?

As of 28-Jul, Titan Biotech Ltd is experiencing a decline in its stock price, currently at 440.35, reflecting a decrease of 5.65 or 1.27%. The stock has underperformed its sector by 0.66% today and has been on a consecutive fall for the last three days, accumulating a total decline of 2.43% during this period. Over the past week, the stock has decreased by 3.44%, while it has shown a positive return of 9.61% over the last month. However, the company has reported negative results for the last three consecutive quarters, with a significant drop in profit before tax and a decline in profit after tax. Additionally, despite a high return on equity of 25.08%, the stock is considered expensive with a price-to-book value of 2.4, which may deter investors.
In the broader market context, Titan Biotech's performance has been notably weaker compared to the benchmark, with a year-to-date return of -39.90% against the Sensex's positive return of 3.52%. The stock's long-term growth prospects appear poor, as indicated by the annual growth rates of net sales and operating profit over the last five years, which are relatively low. This underperformance is further highlighted by the stock's return of -24.15% over the past year, significantly worse than the BSE500's decline of only -2.52%. The combination of disappointing financial results and high valuation relative to peers contributes to the stock's downward trajectory in the current market environment.